Dinaciclib (SCH-727965)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:59, 16 January 2015 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9. ==Preliminary data== ===[[Multiple...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9.

Preliminary data

Multiple myeloma

  1. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2014 Nov 13. [Epub ahead of print] link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Dinaciclib_(SCH-727965)&oldid=6811"